UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance.
Analysts have said the FDA’s request for a new trial will delay Novartis’ intrathecal formulation of its spinal muscular atrophy (SMA) gene therapy in older patients until 2023, potentially
The pharmaceutical industry is at an inflection point, where ground-breaking innovation must be translated into transformational value for patients, healthcare professionals and society.
Health systems in lower-income countries could overtake those in richer countries with AI-enabled technologies, according to a report from Novartis Foundation and Microsoft.
A first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid leukaemia (CML) in a head-to-head trial, setting up reg